Cerebral Safety, Regulation & Compliance: An Independent Assessment

Cerebral's Business Model and Clinical Scope

Cerebral operates as a subscription-based telehealth platform connecting patients with prescribers and therapists for common psychiatric conditions. The company treats anxiety, depression, ADHD, insomnia, and bipolar disorder through a combination of medication management and talk therapy.

Patients can choose from tiered monthly plans. The medication-management-only plan costs approximately $85 per month for those paying cash. Plans that bundle therapy sessions range from $259 to $325 per month. Cerebral also accepts insurance from major carriers including Aetna, Cigna, Anthem, and some Blue Cross Blue Shield plans, though covered services and copays vary by state and plan type.

The model depends on asynchronous intake questionnaires followed by video visits with licensed prescribers. A typical new-patient evaluation lasts 30 minutes. Follow-up visits for medication management are shorter, often 15 minutes. The American Psychiatric Association's position statement on telehealth supports synchronous video-based psychiatric evaluation as clinically appropriate for many conditions, provided that prescribers adhere to the same standards of care as in-person visits [1]. The speed and accessibility of this model drove rapid growth: Cerebral reportedly enrolled over 700,000 patients within its first two years.

The DOJ Investigation Into Controlled Substance Prescribing

The most consequential regulatory event in Cerebral's history began in 2022, when the U.S. Department of Justice opened an investigation into the company's prescribing of controlled substances, particularly Schedule II stimulants such as Adderall (amphetamine salts) and Ritalin (methylphenidate) for ADHD.

The investigation followed reporting that Cerebral's internal culture pressured clinicians to prescribe stimulants quickly, sometimes after a single brief video visit. Several former prescribers described an environment where patient volume targets conflicted with thorough diagnostic evaluation. ADHD diagnosis requires careful clinical assessment. The DSM-5 diagnostic criteria specify that symptoms must be present in two or more settings, must have been present before age 12, and must not be better explained by another mental disorder [2].

CVS Health stopped filling Cerebral's prescriptions for Schedule II controlled substances in May 2022. Walmart followed with similar restrictions. These pharmacy-level refusals are unusual and signaled serious concern about prescribing patterns.

In response, Cerebral announced it would no longer prescribe stimulants to new patients on their first visit and implemented a multi-visit assessment protocol for ADHD. The company also required standardized rating scales (such as the Adult ADHD Self-Report Scale) and collateral information before initiating stimulant therapy. The Substance Abuse and Mental Health Services Administration (SAMHSA) has emphasized that prescribing controlled substances via telehealth requires the same diligence as in-person prescribing, including appropriate monitoring and follow-up [3]. As of 2026, the DOJ investigation has not resulted in criminal charges, but it remains a material factor in evaluating the platform's compliance posture.

The FTC Enforcement Action and Patient Data Privacy

In 2023, the Federal Trade Commission filed a complaint against Cerebral for sharing sensitive patient health information with third-party advertising platforms without adequate patient consent. The FTC alleged that Cerebral used tracking pixels from Meta (Facebook), Google, TikTok, and Snapchat on its platform, transmitting identifiable health data, including mental health conditions, prescription information, and appointment details, to these companies for advertising purposes.

The resulting consent order required Cerebral to pay $7.1 million in penalties and imposed strict prohibitions on future data sharing with advertising platforms [4]. The FTC also required the company to implement a comprehensive privacy program subject to third-party auditing for 20 years.

This enforcement action was not unique to Cerebral. The FTC pursued similar cases against BetterHelp and GoodRx for comparable pixel-tracking practices. A 2023 study published in Health Affairs found that 49 of 50 top telehealth websites used tracking technologies that could transmit patient data to third parties, suggesting the problem was industry-wide [5]. That context does not excuse Cerebral's conduct, but it frames the violation within a broader pattern of digital health data mishandling.

For patients, the practical concern is whether their health information was used to target them with ads. The FTC order requires Cerebral to notify affected users and delete improperly shared data. Cerebral has stated it removed all third-party tracking pixels from its clinical platform.

State-Level Regulatory Compliance

Telehealth prescribing is governed by a patchwork of state laws, and Cerebral must comply with regulations in every state where it operates. Several states tightened telehealth prescribing rules after the federal COVID-era flexibilities expired.

The Ryan Haight Act requires practitioners to conduct at least one in-person evaluation before prescribing controlled substances via telehealth, though the DEA issued temporary exemptions during the COVID-19 public health emergency that have been repeatedly extended [6]. Cerebral initially relied on these exemptions to prescribe stimulants via video-only visits. As states like Texas, Florida, and Ohio have implemented their own telehealth prescribing restrictions, Cerebral has had to adapt its protocols state by state.

The company holds state-level business licenses and its clinicians maintain active licensure in the states where they practice. This basic compliance requirement is often overlooked in evaluations, but it matters. Some smaller telehealth startups have operated in states where their providers were not properly licensed. Cerebral has not faced enforcement actions related to provider licensure.

Clinical Quality and Prescribing Safeguards

Evaluating clinical quality at a telehealth platform with thousands of providers is difficult from the outside. Cerebral publishes limited outcomes data.

What is publicly verifiable: the company now uses structured diagnostic assessments for ADHD, depression (PHQ-9), and anxiety (GAD-7). The PHQ-9 is validated with a sensitivity of 88% and specificity of 88% for detecting major depression at a cutoff score of 10 [7]. These are standard instruments used across psychiatry and primary care. Their presence in the workflow is necessary but not sufficient for quality care. The clinical judgment applied to results matters more than the fact that the screener was administered.

Cerebral's prescribing formulary includes SSRIs (sertraline, escitalopram, fluoxetine), SNRIs (venlafaxine, duloxetine), bupropion, buspirone, hydroxyzine, and, for ADHD, stimulants (with the new multi-visit protocol) and non-stimulant alternatives like atomoxetine. The company does not prescribe benzodiazepines. This formulary restriction is a meaningful safety signal. Benzodiazepine prescribing in telehealth carries well-documented risks of dependence and diversion, and avoiding them entirely demonstrates a conservative approach to controlled substance management [8].

For medication monitoring, Cerebral requires follow-up visits within 30 days of initiating a new medication and quarterly check-ins thereafter. The American Academy of Family Physicians recommends follow-up within 4 to 6 weeks of starting antidepressants to assess response and side effects [9]. Cerebral's 30-day window falls within this standard.

Leadership Transitions and Organizational Response

Cerebral's founding CEO, Kyle Robertson, stepped down in May 2022 amid the DOJ investigation and mounting criticism of the company's prescribing culture. David Mou, MD, MPH, a psychiatrist and former medical director at the company, assumed the CEO role. The transition from a non-clinician founder to a physician CEO was intended to signal a reorientation toward clinical governance.

Under Mou's leadership, Cerebral implemented several structural changes: a medical advisory board with external psychiatrists, mandatory clinical supervision ratios, a peer-review process for prescribing outliers, and a compliance department that reports directly to the CEO rather than through operations. Whether these changes are cosmetic or substantive depends on execution, and independent verification is limited. The company has not published a third-party clinical audit.

A 2021 analysis in JAMA Network Open found that telehealth visits for mental health increased 556% during 2020 compared with the prior year, creating demand that outpaced the workforce capacity to deliver careful evaluations [2]. Cerebral's early missteps occurred during this exact surge. That context explains the pressures but does not eliminate the responsibility.

How Cerebral Compares to Competitors on Safety Metrics

Several telehealth mental health platforms compete with Cerebral, including Done, Talkiatry, Brightside, and the therapy-focused BetterHelp. A fair comparison requires looking at the same dimensions: regulatory actions, prescribing controls, and data practices.

Done, another ADHD-focused telehealth company, faced its own DOJ investigation and its founder was arrested in 2024 on charges of conspiracy to commit health care fraud related to stimulant prescribing. Talkiatry, which operates on an insurance-based model with employed psychiatrists rather than contracted prescribers, has not faced comparable regulatory actions. BetterHelp settled its own FTC complaint over data sharing for $7.8 million, a sum comparable to Cerebral's settlement.

The distinguishing factor among these platforms is governance structure. Companies that employ clinicians directly (like Talkiatry) typically exert more control over clinical standards than those using independent contractor models. Cerebral uses a mix of employed and contracted clinicians, which creates variable oversight depending on the state and provider arrangement. The National Academy of Medicine's report on clinician well-being has noted that production-pressure environments in healthcare correlate with lower quality and higher burnout, regardless of the care setting [10].

Patients comparing platforms should ask three questions: Does the platform restrict first-visit controlled substance prescribing? Has the company faced and resolved regulatory actions transparently? Does the company accept insurance, reducing the financial incentive to retain patients through unnecessary prescriptions?

What Prospective Patients Should Know Before Signing Up

Cerebral is a licensed, operational telehealth platform that provides legitimate psychiatric services. That sentence would not need stating if the company's regulatory history were cleaner. The facts require a more specific assessment.

The strengths are real. Cerebral accepts insurance, which reduces out-of-pocket costs significantly compared with cash-only competitors. Wait times for an initial appointment are typically under two weeks, far shorter than the average 25-day wait for an outpatient psychiatry appointment reported in a 2023 survey of U.S. metro areas [11]. The platform covers all 50 states, addressing geographic access gaps in a specialty where roughly 60% of U.S. counties have no practicing psychiatrist according to data from the Health Resources and Services Administration [12].

The risks are also real. The company's data-sharing practices violated patient trust in a measurable, FTC-documented way. The DOJ investigation into prescribing practices remains unresolved. Internal clinical governance reforms are self-reported and not independently verified.

Patients considering Cerebral should request a copy of the platform's current privacy policy before their first visit, confirm that their specific insurance plan is accepted (not just the carrier), and ask their prescriber directly about the assessment protocol for their condition. The Agency for Healthcare Research and Quality recommends that patients actively participate in treatment decisions and ask about the evidence base for any prescribed medication [13]. That advice applies with equal force in a telehealth setting.

Anyone prescribed a controlled substance through Cerebral or any telehealth platform should ensure they have a follow-up scheduled within 30 days, know the specific monitoring plan for their medication, and have a clear path to reach their prescriber between visits for urgent concerns.